Thrombocytopenia. Thrombocytopenia, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Patients will receive 100 micrograms of coenzyme Q10 daily for a duration of 10 days. Intervention 2: Control group: Patients will receive one placebo pill each day
Sponsors
Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Intensive care unit stay for for at least 72 hours Patients receiving linezolid Patients who sign an informed consent form Documented or possible staphylococcal infections
Exclusion criteria
Exclusion criteria: Incomplete information in the file Lack of consent of the patient or his/her companions to participate in the study Treatment with the drug Coenzyme Q10
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet Count. Timepoint: Day 7, 10. Method of measurement: Complete Blood Count (CBC).;Serum sodium concentration. Timepoint: Day 10. Method of measurement: Lab data. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of gastrointestinal, cardiovascular, and metabolic complications in the intervention group compared to the control group. Timepoint: Day 10. Method of measurement: The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Event. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactForoud Shahbazi
Kermanshah University of Medical Sciences
Outcome results
None listed